Andrew M. Alul focuses his practice primarily on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the U.S. Food and Drug Administration (FDA).
Andrew has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.
Andrew is also experienced in negotiating settlements of intellectual property disputes, particularly drug patent disputes, and in employing licensing strategies that benefit clients.
Andrew counsels clients on issues arising under the newly enacted Leahy-Smith America Invents Act (AIA), including opposition procedures such as post-grant and inter partes reviews, and including changes in the law to patentability and novelty.
Prior to joining Taft, Andrew was a partner at Rakoczy Molino Mazzochi Siwik LLP and an associate at Schiff Hardin LLP and at Leydig, Voit & Mayer, Ltd.
Rate : $$$